Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYS6017
- Development stage
- Phase 2
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
SYS6017 is an mRNA vaccine developed for the prevention of herpes zoster (shingles), caused by the varicella-zoster virus (VZV). The vaccine consists of mRNA molecules encoding the glycoprotein E (gE) of VZV, encapsulated in a lipid nanoparticle formulation. This design allows induction of both humoral and cellular immune responses against VZV. It is currently being developed by CSPC Pharmaceutical Group, and has obtained clinical trial approval from the National Medical Products Administration (NMPA) of China. Preclinical data indicate good safety and immunogenicity, with potential for fewer adverse reactions compared to existing vaccines. There are currently no mRNA-based VZV vaccines on the market[1][3][9].
- Other names
- SYS6017YSYS-6017YSYS 6017Y
02
Targets
gE (VZV glycoprotein E)
Beyond the preview
Go deeper on SYS6017.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYS6017.